| 引用本文: | 王丹丹,孙健伟,张磊,张家洁.鼠神经生长因子对早产儿脑损伤血清神经损伤标志物和神经行为学的影响[J].中国现代应用药学,2020,37(1):74-77. |
| WANG Dandan,SUN Jianwei,ZHANG Lei,ZHANG Jiajie.Effects of Mouse Nerve Growth Factor on Serum Nerve Injury Markers and Neuroethology in Premature Infants with Brain Injury[J].Chin J Mod Appl Pharm(中国现代应用药学),2020,37(1):74-77. |
|
| 摘要: |
| 目的 探究和分析鼠神经生长因子对早产儿脑损伤血清神经损伤标志物和神经行为学的影响。方法 选取河南省人民医院2016年2月-2018年2月早产脑损伤患儿160例，随机分为对照组和观察组，每组各80例，对照组使用常规治疗方法并每日静脉滴注胞二磷胆碱钠注射液，观察组在对照组基础上加用鼠神经生长因子肌肉注射，评估疗效、神经行为，分别检测治疗前后血清糖分解烯醇酶（serum neuron-specific enolase，NSE）、胶质纤维酸性蛋白（glial fibrillary acidic protein，GFAP）、髓鞘碱性蛋白（myelin basic protein，MBP）、S100钙结合蛋白β（S100 calcium-binding protein β，S-100β）和Toll样受体-4（Toll-like receptor-4，TLR-4）的含量，并观察治疗期间不良反应发生情况。结果 观察组改善率为93.75%，对照组改善率为72.50%，明显低于观察组（χ2=16.10，P<0.05）；治疗后2组各项新生儿神经行为测定评分均明显升高（P<0.05），观察组较对照组更明显（P<0.05）；2组治疗后NSE、GFAP、MBP、S-100β和TLR-4较治疗前明显下降（P<0.05），观察组较对照组更明显（P<0.05）；对照组和观察组不良反应发生情况差异不显著。结论 鼠神经生长因子治疗能明显提升脑损伤早产儿临床疗效，改善各项血清学指标，改善患儿神经行为，且临床用药安全。 |
| 关键词: 鼠神经生长因子 早产儿脑损伤 血清神经损伤标志物 神经行为学 |
| DOI：10.13748/j.cnki.issn1007-7693.2020.01.014 |
| 分类号:R969.4 |
| 基金项目:河南省医学科技攻关计划项目（201503162） |
|
| Effects of Mouse Nerve Growth Factor on Serum Nerve Injury Markers and Neuroethology in Premature Infants with Brain Injury |
|
WANG Dandan, SUN Jianwei, ZHANG Lei, ZHANG Jiajie
|
|
Henan Provincial People's Hospital, Zhengzhou 450000, China
|
| Abstract: |
| OBJECTIVE To explore and analyze the effects of mouse nerve growth factor on serum nerve injury markers and neuroethology in premature infants with brain injury. METHODS One hundred and sixty premature infants children patients with brain injury from February 2016 to February 2018 in Henan Provincial People's Hospital were selected and randomly divided into control group and observation group, with 80 cases in each group. Control group was given routine treatment and daily intravenous infusion of cytidine diphosphate choline injection, and observation group was supplemented with intramuscular injection of mouse nerve growth factor on the basis of control group. The efficacy and neurobehavior were evaluated. Serum neuron-specific enolase(NSE), glial fibrillary acidic protein(GFAP), myelin basic protein(MBP), S100 calcium-binding protein β(S-100β) and Toll-like receptor-4(TLR-4) were measured before and after treatment, and the occurrence of adverse reactions during treatment was observed. RESULTS The improvement rate of observation group was 93.75%, which was significantly higher than that of control group(72.50%)(χ2=16.10, P<0.05). The neonatal behavioral neurological assessment in the two groups were significantly increased after treatment(P<0.05), it were more significant in observation group compared with control group(P<0.05). The levels of of NSE, GFAP, MBP, S-100β and TLR-4 after treatment were significantly decreased compared with those before treatment(P<0.05), and it were more significant in observation group compared with control group(P<0.05). There was no significant difference in the occurrence of adverse reactions between control group and observation group. CONCLUSION Mouse nerve growth factor therapy can significantly improve the clinical efficacy of premature infants with brain injury, enhance various serological indicators, and improve neurobehavior and it will not increase adverse reactions. Moreover, it is safe in the clinical practice. |
| Key words: mouse nerve growth factor premature infants with brain injury serum nerve injury markers neuroethology |
